Page URL: https://www.bionews.org.uk/page_160760

Cancer cells grow by sucking mitochondria out of immune cells

29 November 2021
Appeared in BioNews 1123

Cancer cells can form tentacle-like structures to steal energy-producing mitochondria from immune cells, according to new research.

Cancers must evade the immune system to progress. Gaining a better understanding of how cancer cells do this is critical in the search for the development of next-generation immunotherapies. Cells can form connections via nanotubes – tiny structures made up of the protein actin – to transport materials between them. By using these structures to hijack immune cells' mitochondria cancer cells can gain power to grow and divide more quickly, while depleting the immune cells' ability to function.

'Cancer kills when the immune system is suppressed and cancer cells are able to metastasise, and it appears that nanotubes can help them do both,' said corresponding author Dr Shiladitya Sengupta from the Brigham and Women's Hospital in Boston, Massachusetts. This is a completely new mechanism by which cancer cells evade the immune system and it gives us a new target to go after.' 

Researchers from the Centre for Brigham and Women's Hospital and MIT in Massachusetts grew mouse immune and cancer cells together in a dish for 16 hours and used field-emission scanning electron microscopy to take a snapshot of the interactions that formed. The results, published in Nature Nanotechnology, showed that, on average, each cancer cell formed one nanotube connection with an immune cell called a T-cell. The connected cancer cells consumed double the amount of oxygen and divided more often than cancer cells that had been grown close to, but physically apart from T-cells. The oxygen consumption of the T-cells and their numbers decreased significantly when they were in contact with the cancer cells.

The same results were found in human thymus and breast cancer cells. The researchers used fluorophore-tagged mitochondria and discovered that they were transported along the nanotubes from the T-cells to the cancer cells.

The researchers used a drug that partially inhibited the formation of nanotubes, together with the clinically available checkpoint inhibitor PD-1 in mice, and found that it reduced the tumour size and increased the number of T-cells present in the tumours. 

Lead author Dr Tanmoy Saha from the Centre for Engineered Therapeutics at the Brigham and Women's Hospital said 'One of the goals in cancer immunotherapy is to find combinations of therapies that can improve outcomes. Based on our observations, there is evidence that an inhibitor of nanotube formation could be combined with cancer immunotherapies and tested to see if it can improve outcomes for patients.'

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
15 March 2021 - by Dr Charlott Repschlager 
Breast cancer brain metastases can be targeted with a new approach using stem cells as a delivery system...
24 June 2019 - by Dr Lea Goetz 
The rapid annual regrowth of deer antlers is down to a combination of cancer-linked genes and tight regulation of them by tumour-suppressing genes, finds a new study. The results may offer a new avenue for cancer treatment research in humans...
7 May 2019 - by Georgia Everett 
Researchers have discovered that the deletion of a single gene can halt the development and progression of aggressive pancreatic cancer in mice...
12 February 2018 - by Dr Nicoletta Charolidi 
Blocking a single molecule, the amino acid asparagine, can prevent breast cancer spread in mice, according to a new study...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.